Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Pipeline

DCC-2618 KIT, PDGFRα
REBASTINIB TIE2
DCC-3014 CSF1R

Investors

DCPH

$27.96

0.00
12/07/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Nov
20
2018
Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference Read More »
Nov
15
2018
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors Read More »
Nov
08
2018
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results Read More »